New use of eucommia ulmoides male flower pollen and / or eucommia ulmoides male flower and composition comprising same

Abstract

The application discloses a new use of pollen of eucommia ulmoides male flowers or eucommia ulmoides male flowers and a composition containing the same. The composition provided by the application has reasonable components and nutrients, and has the effects of improving sperm quality and improving male reproductive function.

Description

Technical Field

[0001] This invention relates to the fields of food, health food, or pharmaceuticals, specifically to the use of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower to improve male sperm quality and compositions containing the same, which are used to improve sperm quality in men trying to conceive and in men with oligospermia, asthenospermia, sperm malformation, or low sperm motility. Background Technology

[0002] On April 3, 2023, the World Health Organization (WHO) released a report titled "Estimations of Infertility Prevalence (1990-2021)," which showed that approximately 17.5% of adults worldwide (about one-sixth of the population) are affected by infertility. The report indicated that infertility prevalence varies across different regions of the world. The highest lifetime prevalence is in the Western Pacific region (23.2%), followed by the Americas (20%) and Europe (16.5%), while the Mediterranean region has the lowest (10.7%). Infertility prevalence is almost uniform across different income levels, with 17.8% in high-income countries and 16.5% in low- and middle-income countries. Of particular concern is that in just 45 years, from 1973 to 2018, the average sperm count of men worldwide decreased by 62%, and sperm concentration in semen decreased by 52%. The global rate of decline in sperm concentration was approximately 1.16% per year, increasing to 2.64% after 2000. A nationwide epidemiological survey of reproductive health conducted by Academician Qiao Jie's team at Peking University shows that between 2007 and 2020, the incidence of infertility in my country rose from 12% to 18%, with more than 60 million patients. Predicted data indicates that my country's infertility rate will reach 18.2% by 2023. Among infertile patients, factors shared by both men and women account for approximately 20%–30%, while male factors account for approximately 30%–40%. The male infertility rate in my country has reached 10%–15%, accounting for approximately 25%–37% of married couples.

[0003] Currently, common clinical treatments for male infertility include medication, surgery, assisted reproductive technologies, and acupuncture as an adjunct therapy. However, most medications used to treat male infertility are hormones or antibiotics, which have various side effects, necessitating the development of new, safe, and effective products.

[0004] Eucommia male flowers are the flowers of the male tree of Eucommia ulmoides Oliv., a plant belonging to the Eucommiaceae family. They consist of the outer bracts and pollen. In 2014, they were approved as a new food ingredient in my country. Eucommia male flowers are rich in polysaccharides, flavonoids, and other secondary metabolites, as well as iridoids, lignans, and phenylpropanoids. Traditionally, they are believed to have hypoglycemic, laxative, and sedative effects. Modern research suggests they also possess sedative-hypnotic, anti-inflammatory, analgesic, antioxidant, anti-aging, antibacterial, and immunomodulatory pharmacological effects.

[0005] Eucommia ulmoides male flower pollen, found in the flower clusters of male Eucommia ulmoides plants, is rich in nutrients. The content of total amino acids, essential amino acids, vitamin C, and vitamin B is significantly higher than that in the leaves and bark, and the protein content is 8.2% higher than the average of 40 other common pollen species. It also contains various active ingredients, including flavonoids, phenolic acids, iridoids, and lignans, possessing high nutritional value and medicinal and health benefits. Animal experiments have shown that Eucommia ulmoides male flower pollen has significant antioxidant, blood pressure-lowering, and blood lipid-lowering effects, effectively resisting the damage of toxic substances to the body and reducing the toxic side effects of chemotherapy drugs. Summary of the Invention

[0006] In order to improve sperm quality in male infertility patients, especially those with oligospermia, asthenospermia, sperm malformation, and low sperm motility, and to promote eugenics, this invention provides new uses for Eucommia ulmoides male flower pollen or Eucommia ulmoides male flowers and compositions containing them.

[0007] Therefore, the present invention provides the use of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flowers in the preparation of food or medicines that improve sperm quality.

[0008] Preferably, the present invention provides the use of Eucommia ulmoides male flower pollen in the preparation of food or medicines that improve sperm quality.

[0009] Preferably, the improvement of sperm quality includes one or more of the following: improving sperm concentration, enhancing sperm motility, reducing sperm abnormality rate, increasing fertilization probability, and improving serum sex hormone levels.

[0010] Furthermore, the present invention provides a composition for improving sperm quality, wherein the composition comprises pollen from male Eucommia ulmoides flowers or male Eucommia ulmoides flowers.

[0011] Preferably, the composition contains 0.1% to 99.9% by weight of Eucommia ulmoides male flower pollen or Eucommia ulmoides male flower.

[0012] Preferably, the composition contains at least pollen from male Eucommia ulmoides flowers.

[0013] Preferably, the composition further comprises astaxanthin or coenzyme Q10, i.e., either astaxanthin or coenzyme Q10.

[0014] More preferably, the composition further comprises coenzyme Q10.

[0015] In one specific embodiment, the composition comprises Eucommia ulmoides male flower pollen and astaxanthin.

[0016] In one specific embodiment, the composition comprises Eucommia ulmoides male flowers and astaxanthin.

[0017] In one embodiment, the composition comprises Eucommia ulmoides male flower pollen, Eucommia ulmoides male flower, and astaxanthin.

[0018] In one embodiment, the composition comprises Eucommia ulmoides male flower pollen and coenzyme Q10.

[0019] In one specific embodiment, the composition comprises Eucommia ulmoides male flowers and coenzyme Q10.

[0020] In one embodiment, the composition comprises Eucommia ulmoides male flower pollen, Eucommia ulmoides male flowers, and coenzyme Q10.

[0021] The weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower to astaxanthin is 50:0.1-400, preferably 50:1-200, and more preferably 50:5-50.

[0022] In one specific embodiment, the weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower to astaxanthin is 50:20.

[0023] The weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower to coenzyme Q10 is 50:0.1-100, preferably 50:0.5-80, and more preferably 50:1-50.

[0024] In one specific embodiment, the weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower to coenzyme Q10 is 50:20.

[0025] Preferably, the composition further comprises astaxanthin and coenzyme Q10.

[0026] In one specific embodiment, the composition includes Eucommia ulmoides male flower pollen, astaxanthin, and coenzyme Q10.

[0027] In one specific embodiment, the composition includes Eucommia ulmoides male flowers, astaxanthin, and coenzyme Q10.

[0028] In one embodiment, the composition comprises Eucommia ulmoides male flower pollen, Eucommia ulmoides male flower, astaxanthin, and coenzyme Q10.

[0029] The weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower: astaxanthin: coenzyme Q10 is 50:0.1-400:0.1-100, preferably 50:0.5-200:0.5-80, more preferably 50:0.5-50:0.5-50, and even more preferably 50:0.8-30:0.8-30.

[0030] In one specific embodiment, the weight ratio of Eucommia ulmoides male flower pollen and / or Eucommia ulmoides male flower: astaxanthin: coenzyme Q10 is 50:5:5.

[0031] Preferably, the composition is prepared as food or medicine.

[0032] Preferably, the food is a health food, functional food, nutritional meal plan food, medicinal food, or special dietary food.

[0033] Preferably, the food or medicine is in solid dosage form or liquid oral dosage form.

[0034] The composition provided by this invention is formulated and combined according to the latest theories of modern life science to find the optimal ratio. Different combinations and ratios have the effects of improving sperm concentration, enhancing sperm motility, and reducing sperm abnormality rate, while increasing the chance of fertilization. In other words, the composition of this invention has a proper combination of components and reasonable nutrition, which can improve sperm quality and male reproductive function. Detailed Implementation

[0035] Example 1: Study on the efficacy of Eucommia ulmoides male flower pollen in improving adenine-induced reproductive damage in SD rats

[0036] (1) Experimental apparatus

[0037]

[0038] (2) Drug testing

[0039] Sodium pentobarbital [Beijing Puris Biotechnology Co., Ltd.]; Sodium carboxymethyl cellulose [Sinopharm Chemical Reagent Co., Ltd.]; Xanthan gum [9k8712k]; Eucommia ulmoides male flower pollen [origin: Henan]. The term "pollen" below has the same meaning as "Eucommia ulmoides male flower pollen".

[0040] Animals: SPF-grade male SD rats, 10-11 weeks old, weighing 350±20g; SPF-grade female SD rats, 9-10 weeks old, weighing 330±20g.

[0041] (3) Solution preparation

[0042] Preparation of 0.3% xanthan gum aqueous solution: Take about 6g of xanthan gum solid powder, weigh it accurately, and put it into a glass mortar. Prepare it by adding water in equal increments. First, add a little water and grind it evenly. Then add water of the same volume as the mixture in the mortar and grind it evenly again until all the water is added, so that the final concentration is 0.3%.

[0043] Preparation of pollen suspension: Weigh approximately 3.5g of Eucommia ulmoides male flower pollen precisely, place it in a glass mortar, and gradually add 100mL of 0.3% xanthan gum solution using the equal-increment method. Grind thoroughly to ensure uniform suspension, so that the final concentration of Eucommia ulmoides male flower pollen is 70.0mg / mL. Store at 4℃ for later use.

[0044] Positive control drug L-carnitine solution: Take 10 mL of L-carnitine oral solution, dilute with 0.3% xanthan gum solution to 100 mL, mix well, and you will get a final concentration of 10 mg / mL L-carnitine solution. Store at 4℃ for later use.

[0045] Preparation of adenine suspension: Weigh approximately 1.5g of adenine powder accurately and place it in a glass mortar. Gradually add 0.3% xanthan gum solution using the equal-increment method, and grind thoroughly to ensure uniform suspension. This yields a pollen suspension with a final concentration of 15mg / mL. Store at 4℃ for later use.

[0046] Grouping and administration of experimental animals

[0047] Seventy male SD rats were placed in a clean-grade animal room at a room temperature of 22–26°C, with free access to food and water. After one week of acclimatization, they were randomly divided into three groups according to their body weight: normal group, model group, Eucommia ulmoides male flower pollen group (referred to as pollen group), and L-carnitine positive drug group (referred to as positive group), with 10 rats in each group.

[0048] Normal group: fed water; Model group: fed 0.3% xanthan gum solution in the morning, followed by adenine suspension 4 hours later; Pollen group: fed pollen suspension (dosage: 350 mg / kg / day) in the morning, followed by adenine suspension (dosage: 150 mg / kg) 4 hours later; Positive control group: fed L-carnitine solution (dosage: 100 mg / kg / day) in the morning, followed by adenine suspension (dosage: 150 mg / kg) All feeding volumes were 10 mL / kg / time. All drugs were prepared with 0.3% xanthan gum solution, administered at a volume of 1 mL / 100g, once daily. The total experimental duration was 30 days, with adenine suspension administered for 15 days. The dosage of Eucommia ulmoides male pollen was twice the human dose. Weight was recorded every 7 days during the experiment, and dosages were adjusted accordingly. Thirty days after administration, patients were kept on a fast but allowed free access to water for 12 hours. Blood was drawn from the abdominal aorta, centrifuged, and the serum was removed to determine relevant indicators. Kidneys, testes, epididymis, prostate, seminal vesicles, and brains were collected, weighed, and the visceral brain index was calculated (visceral brain index = organ weight / brain weight).

[0049] Indicator Monitoring and Results

[0050] (1) General condition of rats

[0051] After a period of gavage administration of adenine suspension, rats gradually developed symptoms of kidney yang deficiency, including decreased water intake, increased urine output, and reduced activity. With prolonged gavage, they gradually exhibited weight loss, lethargy, arched back and curled-up posture, cold intolerance, sparse and dull fur, and other signs. The normal control group showed no abnormalities in weight, food intake, or responsiveness. In the treatment group, these symptoms gradually improved with prolonged gavage.

[0052] (2) Effects of Eucommia ulmoides male flower pollen on body weight and accessory gland tissue in rats with kidney-yang deficiency.

[0053] Effects of Eucommia ulmoides male flower pollen on rat body weight: Table 1 shows that, compared with the normal group, the body weight of rats in all other groups decreased significantly after one week of adenine administration, and the differences were statistically significant (P<0.05). There was no significant difference between the Eucommia ulmoides male flower pollen group and the L-carnitine group, indicating that Eucommia ulmoides male flower pollen and L-carnitine had little effect on the change in rat body weight.

[0054] Table 1. Effects of Eucommia ulmoides male flower pollen on rat body weight

[0055]

[0056] Note: Compared with the normal group: #P<0.05, ##P<0.01; Compared with the model group: *P<0.05, **P<0.01.

[0057] Effects of Eucommia ulmoides male pollen on the kidney, testis, epididymis, prostate, seminal vesicle, and brain indices in rats

[0058] Table 2 shows that, except for the normal group, the kidney-brain index was significantly increased in all other groups (P<0.01), while the indices of the testis, epididymis, prostate, and seminal vesicles with the brain were significantly decreased (P<0.01 or P<0.05), with statistically significant differences. Compared with the model group, the kidney-brain index decreased by approximately 9% and 12% in the Eucommia ulmoides male pollen group and the L-carnitine positive group, respectively, while the indices of all other organs and brains increased. The testis-brain index and seminal vesicle-brain index were significantly improved in the Eucommia ulmoides male pollen group and the L-carnitine group (P<0.05). Organ-brain index = organ mass (g) / brain mass (g).

[0059] Table 2. Effects of Eucommia ulmoides male flower pollen administration for 30 days on the brain index of the kidney, testis, epididymis, prostate, and seminal vesicle in rats.

[0060]

[0061] Note: Compared with the normal group #P<0.05, ## P < 0.01; compared with the model group, *P < 0.05, **P < 0.01

[0062] (3) Fertility testing

[0063] On day 21 after the start of drug administration, females and males were caged together at a 1:1 ratio. Starting from day 2 after caged together, the appearance of vaginal plugs in female mice was observed at 8:00 AM every day. After the vaginal plugs were observed, the males and females were separated and this was taken as day 0 of conception. On day 18 of conception, the pregnant mice were dissected to observe and calculate the conception rate, number of live fetuses, number of resorbed fetuses, number of implantation glands, and number of fetuses.

[0064] Table 3 shows that, compared with the normal group, the model group rats had significantly lower conception rate and number of fetuses. The pollen group and positive group rats had higher conception rate, total number of fetuses, number of live fetuses and number of implantation glands, and the pollen group had a higher live fetus rate.

[0065] Table 3. Effects of Eucommia ulmoides male flower pollen on embryonic development in pregnant mice.

[0066]

[0067] (4) Effects of Eucommia ulmoides male flower pollen on sperm count and sperm motility

[0068] Tissue from the tail of the left epididymis was excised and placed in an EP tube preheated to 37°C (containing 4 mL of PBS buffer). The tissue was then cut into small pieces and shaken. The tissue was incubated in a 37°C water bath for 5 minutes to allow the sperm to release into the solution on their own, thus forming a suspension. After thorough mixing, 100 μL of the suspension was taken and diluted 5 times with PBS. 8 μL of the sperm suspension was then placed on a glass slide, and sperm counts and motility were recorded using a sperm analyzer.

[0069] The results in Table 4 show that, compared with the normal group, the sperm count of rats in the model group was reduced (P<0.01) and the sperm motility was significantly reduced, with statistically significant differences (P<0.01). Compared with the model group, the sperm count and sperm motility of the pollen group and the positive group were significantly increased and recovered to or exceeded the normal level, and the effect of the Eucommia ulmoides male pollen group was better.

[0070] Table 4. Effects of Eucommia ulmoides male flower pollen on sperm count and sperm motility in rats.

[0071]

[0072] Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01

[0073] (5) Comparative analysis of serum sex hormone levels in different groups of animals

[0074] On day 30, after administration, the patient was kept on a fasting and water-free period of 12 hours. Anesthesia was administered via intraperitoneal injection of 1% sodium pentobarbital. Blood was drawn from the abdominal aorta into a vacuum blood collection tube and allowed to stand for about 4 hours. After the blood had clotted, the centrifugation was performed at 3500 rpm for 10 minutes. The serum was then collected and stored at -80°C for later testing.

[0075] Table 5 shows that, compared with the normal group, the model group had decreased serum testosterone (T) levels and increased levels of LH, GnRH, FSH, and E2, with statistically significant differences (P<0.01 or P<0.05). FSH and E2 levels were also increased. Treatment with Eucommia ulmoides male flower pollen increased serum testosterone (T) levels, while LH, FSH, E2, and GnRH levels were lower than in the model group, with no significant difference between the pollen group and the normal group. Compared with the model group, the positive group only showed a significant decrease in LH levels (P<0.05), while FSH and T levels showed some improvement. In summary, Eucommia ulmoides male flower pollen was superior to L-carnitine in improving serum sex hormone levels.

[0076] Table 5. Analysis of serum neutral hormone levels by pollen from Eucommia ulmoides male flowers.

[0077]

[0078] Note: Compared with the model group, *P<0.05, **P<0.01; compared with the normal group, #P<0.1, ##P<0.05

[0079] Example 2: Effects of the composition on sperm count, sperm motility, and improvement of female mouse conception rate

[0080] The experimental procedure was the same as in Example 1. The experimental groups were: normal group, model group, Eucommia ulmoides male flower pollen group, Eucommia ulmoides male flower group, coenzyme Q10 group, astaxanthin group, pollen + astaxanthin group, pollen + coenzyme Q10 group, and pollen + astaxanthin + coenzyme Q10 group. The composition of the test drugs in each group is shown in Table 6. Normal group: fed water; Model group: fed 0.3% xanthan gum solution in the morning, followed by adenine suspension at 150 mg / kg 4 hours later; Pollen group and other groups: fed pollen / test drug suspension (dosage shown in Table 6) in the morning, followed by adenine solution at 150 mg / kg 4 hours later, with a feeding volume of 10 mL / kg / time. All drugs were prepared with 0.3% xanthan gum solution, with a dosage of 1 mL / 100g, once daily. The total experimental duration was 30 days, with adenine administration for 15 days. The pollen from the male flowers of Eucommia ulmoides was equivalent to twice the human dose. During the experiment, the mice were weighed every 7 days, and the weight was recorded to adjust the dosage. On day 21 after the start of administration, the mice were housed in a 1:1 female-to-male ratio. Starting from day 2 after house-house administration, the appearance of the vaginal plug in the female mice was observed at 8:00 AM every day. Once the vaginal plug was observed, the males and females were separated, and this was considered day 0 of conception. On day 18 of conception, the pregnant mice were dissected to observe and calculate the conception rate, number of live fetuses, number of resorbed fetuses, number of implantation glands, and number of fetuses. After 30 days of administration, the male mice were fasted but allowed free water for 12 hours, and semen was extracted from the epididymis to determine sperm motility and count.

[0081] Table 6. Drug composition and dosage for each treatment group

[0082]

[0083] Note: "Part" refers to "portions by weight".

[0084] Table 7. Effects of different groups on sperm count and sperm motility in rats.

[0085]

[0086] Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01

[0087] As shown in Table 7, the Eucommia ulmoides male flower pollen group was more effective than the Eucommia ulmoides male flower group in improving sperm count and motility, indicating that the Eucommia ulmoides male flower pollen has superior activity. Comparing Eucommia ulmoides male flower pollen alone with astaxanthin or coenzyme Q10 alone, the effect of Eucommia ulmoides male flower pollen alone was also superior to that of astaxanthin or coenzyme Q10 alone, especially since astaxanthin alone did not improve sperm count and motility. Looking at the various compositions containing Eucommia ulmoides male flower pollen, all groups significantly improved sperm quality, increased sperm count and motility, and the composition groups were superior to the pollen-only groups, showing a synergistic effect. In particular, the three-component combination achieved optimal effects for each component at lower dosages.

[0088] Table 8. Effects of different groups on embryonic development in pregnant rats

[0089]

[0090] As shown in Table 8, all treatment groups improved the conception rate of female mice to varying degrees, with the most significant improvements observed in the Eucommia ulmoides male flower pollen + coenzyme Q10 group and the Eucommia ulmoides male flower pollen + astaxanthin + coenzyme Q10 group. Regarding the number of fetuses, the total number of fetuses in the groups containing Eucommia ulmoides male flower pollen was significantly higher than that in the groups without pollen and the model group, and the live birth rate was also higher in the groups containing Eucommia ulmoides male flower pollen. Compared to the pollen-only group, the combined groups, especially the combination containing pollen + coenzyme Q10, showed better live birth rate and total number of fetuses than the pollen-only group. Although astaxanthin itself has little effect on improving conception rate and total number of fetuses, adding a certain amount of astaxanthin to the combined group can have an unexpected synergistic effect, making the pollen's effect more prominent.

[0091] Example 3: Effects of different proportions of the composition on sperm count, sperm motility, and improvement of female mouse conception rate

[0092] The experimental procedure was the same as in Example 1. The experiment was divided into three groups: a treatment group (combinations of different proportions of Eucommia ulmoides male flower pollen, astaxanthin, and coenzyme Q10, and a pollen group), a normal group, and a model group. The composition of the test drugs in each treatment group is shown in Table 9. Normal group: fed water; Model group: fed 0.3% xanthan gum solution in the morning, followed by adenine suspension at 150 mg / kg 4 hours later; Other treatment groups: fed the test drug suspension (dose 350 mg / kg / day) in the morning, followed by adenine solution at 150 mg / kg 4 hours later, with a feeding volume of 10 mL / kg / time. All drugs were prepared with 0.3% xanthan gum solution, administered at a volume of 1 mL / 100g, once daily. The total experimental duration was 30 days, with adenine administration for 15 days. Body weight was recorded every 7 days during the experiment, and the dosage was adjusted accordingly. On day 21 after the start of drug administration, males and females were caged together at a 1:1 ratio. Starting from day 2 after caged together, the appearance of vaginal plugs in female mice was observed at 8:00 AM every day. After the vaginal plugs were observed, the males and females were separated, and this was considered day 0 of conception. On day 18 of conception, pregnant mice were dissected to observe and calculate the conception rate, number of live fetuses, number of resorbed fetuses, number of implantation glands, and number of fetuses. Male mice were fasted for 12 hours after drug administration, but allowed free access to water. Semen was extracted from the epididymis to determine sperm motility and count.

[0093] Table 9. Drug composition and dosage for each treatment group

[0094]

[0095] Note: "Part" refers to "portions by weight".

[0096] Table 10 Effects of different groups on sperm count and sperm motility in rats

[0097]

[0098] Note: Compared with the normal group, #P<0.05, ##P<0.01; compared with the model group, *P<0.05, **P<0.01

[0099] As shown in Table 10, all drug administration groups significantly increased the sperm count and motility in male rats with oligospermia and asthenospermia induced by adenine, and the combined effects of each group were better than those of the group using Eucommia ulmoides male flower pollen alone, all showing a good synergistic effect.

[0100] Table 11 Effects of different groups on embryonic development in pregnant rats

[0101]

[0102] As shown in Table 11, all drug administration groups improved the conception rate of female mice to varying degrees, and the combination groups were significantly better than the groups treated with Eucommia ulmoides male pollen alone. The same trend was observed in the number of fetuses; the combination groups showed a greater improvement in conception rate, with a significantly higher number of fetuses. The live birth rate, except for the combination group 1, was also higher than that of the group treated with Eucommia ulmoides male pollen alone. This may be due to the relatively low levels of astaxanthin and coenzyme Q10 in the combination, suggesting that appropriately increasing the proportion of astaxanthin, especially coenzyme Q10, in the combination could enhance the synergistic effect.

[0103] Based on the above description of the invention, those skilled in the art can fully apply the present invention, and all modifications based on the same principles or similar modifications should be considered to be included within the scope of the present invention.

Claims

1. A composition for improving sperm quality, wherein, The composition is made from Eucommia ulmoides male flower pollen and coenzyme Q10, and the weight ratio of Eucommia ulmoides male flower pollen to coenzyme Q10 is 50:

20.

2. A composition for improving sperm quality, wherein, The composition is made from Eucommia ulmoides male flower pollen, astaxanthin and coenzyme Q10, and the weight ratio of Eucommia ulmoides male flower pollen: astaxanthin: coenzyme Q10 is 50:0.8-30:0.8-30.

3. The composition of claim 2, wherein, The weight ratio of Eucommia ulmoides male flower pollen: astaxanthin: coenzyme Q10 is 50:5:5, 50:1:1, 50:10:5 or 50:5:

10.

4. The composition according to any one of claims 1-3, characterized in that, The composition is prepared into food or medicine.

5. The composition according to claim 4, characterized in that, The food or medicine is in solid dosage form or liquid oral dosage form.

Images